About Genable Technologies
Genable Technologies is a company based in Dublin (Ireland) founded in 2001 by Paul Kenna and Jane Farrar was acquired by Spark Therapeutics in March 2016.. Genable Technologies has raised $8.11 million across 2 funding rounds from investors including Spark Therapeutics, Fountain Healthcare Partners and Delta Partners. Genable Technologies operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Dublin, Ireland
- Founders Paul Kenna, Jane Farrar
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$8.11 M (USD)
in 2 rounds
-
Latest Funding Round
$6.78 M (USD), Series B
Nov 11, 2011
-
Investors
Spark Therapeutics
& 2 more
-
Employee Count
Employee Count
-
Acquired by
Spark Therapeutics
(Mar 07, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Genable Technologies
Genable Technologies has successfully raised a total of $8.11M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $6.78 million completed in November 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $6.8M
-
First Round
First Round
(07 Sep 2004)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2011 | Amount | Series B - Genable Technologies | Valuation |
investors |
|
| Sep, 2004 | Amount | Series A - Genable Technologies | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Genable Technologies
Genable Technologies has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Spark Therapeutics, Fountain Healthcare Partners and Delta Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Risk capital is provided to life sciences entrepreneurs.
|
Founded Year | Domain | Location | |
|
Early stage venture capital is provided to Irish startups.
|
Founded Year | Domain | Location | |
|
Gene therapies for rare diseases including retinal dystrophies are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Genable Technologies
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Genable Technologies
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Genable Technologies Comparisons
Competitors of Genable Technologies
Genable Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Provider of cell therapies to treat cancer and hematologic conditions
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Genable Technologies
Frequently Asked Questions about Genable Technologies
When was Genable Technologies founded?
Genable Technologies was founded in 2001 and raised its 1st funding round 3 years after it was founded.
Where is Genable Technologies located?
Genable Technologies is headquartered in Dublin, Ireland.
Is Genable Technologies a funded company?
Genable Technologies is a funded company, having raised a total of $8.11M across 2 funding rounds to date. The company's 1st funding round was a Series A of $1.33M, raised on Sep 07, 2004.
What does Genable Technologies do?
Provider of gene therapy to treat Retinitis pigmentosa. The first gene medicine - RhoNova formerly known as GT038 - is for the treatment of patients with rhodopsin (RHO)-linked adRP - a debilitating form of inherited blindness resulting from a diverse array of mutations in the RHO gene. It utilizes AAV vectors to obtain expression of RNA interference (RNAi) molecules which suppress the expression of both the faulty and normal gene copies and replaces this with a gene subtly altered to become refractory to suppression but still encoding a normal wild type protein.
Who are the top competitors of Genable Technologies?
Genable Technologies's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Who are Genable Technologies's investors?
Genable Technologies has 3 investors. Key investors include Spark Therapeutics, Fountain Healthcare Partners, and Delta Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.